Lumo Imaging LLC received a $255,999 Small Business Technology Transfer Phase I Project Grant from the National Science Foundation Engineering Directorate to develop dermatologist-level detection of suspicious pigmented skin lesions from high-resolution full-body images. Under this one-year award beginning August 1, 2021, Lumo Imaging will utilize $255,999 to deliver products and services focused on using machine learning and computer vision techniques to analyze full-body skin images and detect...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $978,154 to Surgivance Inc. to further develop their digital pathology "laboratory-in-a-box" solution that rapidly produces and analyzes high-resolution, 3D digital pathology images for skin cancer detection at the point of care. The specific goals are to: 1) refine the AI algorithms for improved detection of basal and squamous cell carcinomas, 2) develop...
Radiosight LLC was awarded a $256,000 Small Business Technology Transfer (STTR) Phase I Project Grant by the National Science Foundation on May 1, 2021 to develop a point-of-care skin cancer imaging device. The award is being carried out under the NSF's Technology, Innovation, and Partnerships program (CFDA 47.084) and will support Radiosight's efforts to advance science and engineering research leading to breakthrough technologies. Specifically, the funding will allow Radiosight to work towards...
The National Cancer Institute (NCI) awarded a $1,729,890 Cooperative Agreement (CFDA 93.395 - Cancer Treatment Research) to Washington University to develop and validate a new 3D skin imaging technology, SkinScan3D, for improved monitoring of Kaposi Sarcoma (KS) treatment response in East Africa. The project has three main components: Refining the SkinScan3D device and usage protocols through human-centered design workshops with clinicians and patients in Uganda and Kenya to ensure the...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $349,878 to the University of Utah to develop an Electrical Impedance Dermography (EID) technology that can distinguish between subtypes of basal cell carcinoma (BCC) and between squamous cell carcinoma (SCC), precancerous actinic keratosis, and benign seborrheic keratosis. The research aims to use machine learning-augmented EID to improve non-invasive diagnostic...
This $700,611 Project Grant, awarded on March 11, 2025 by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, supports a practical randomized controlled trial (RCT) of artificial intelligence (AI) for melanoma diagnosis at Memorial Sloan Kettering Cancer Center (MSK) and Stanford University (SU). The goal is to determine the potential benefits and barriers to clinical adoption of AI-assisted dermoscopy, and to evaluate the impact on the...
The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $413,832 Project Grant to the University of Texas at Austin to develop a "laser microbiopsy" technology for minimally-invasive, precision tumor sampling of melanoma. The goal is to create a pain-free method to extract tissue samples for pathology and molecular analysis, which could improve early melanoma detection and reduce unnecessary biopsies. Over the 3-year project period from August...
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) has awarded a $693,156 Project Grant (CFDA 93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health) to the Dana-Farber Cancer Institute, Inc. (DFCI) to develop artificial intelligence (AI) algorithms for predicting prognosis and optimizing treatment selection for cutaneous squamous cell carcinoma (CSCC), a highly prevalent form of skin cancer. The project aims to train and validate AI...
Visikol Inc. received a $4,103,265 Project Grant award from the National Cancer Institute, a division of the Department of Health and Human Services, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award will support the development of a 3D imaging diagnostic tool to improve characterization of metastatic melanoma in sentinel lymph node biopsies. Visikol will conduct a retrospective clinical study using archived negative sentinel lymph node biopsy tissue blocks to...
This SBIR Phase I award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $295,924 to Biotherapeutics, Inc. to develop a novel topical therapeutic for the treatment of psoriasis. The key objectives are to: 1) characterize the therapeutic efficacy of the new treatment in a mouse model of psoriasis, 2) develop a topical drug product formulation and test its...
SYSTEM FOR DOCUMENTING AND TRACKING SKIN LESIONS - PROJECT SUMMARY THE OBJECTIVE OF THIS STTR PROPOSAL IS TO DEVELOP A SYSTEM FOR LONGITUDINALLY TRACKING THE LOCATIONS AND MORPHOLOGIC CHANGES TO ALL PIGMENTED SKIN LESIONS ON THE PATIENT'S BODY. THE PROPOSED SOFTWARE WILL BUILD ON A PREVIOUSLY DEVELOPED TOTAL BODY PHOTOGRAPHY (TBP) SYSTEM, CALLED LUMO SCANNER, THAT CAN PROVIDE UNPRECEDENTED RESOLUTION ACROSS THE ENTIRE BODY SURFACE. SKIN CANCERS, INCLUDING BOTH MELANOMA AND NON- MELANOMA, ARE THE MOST COMMON TYPE OF CANCER IN THE UNITED STATES. EARLY-STAGE IDENTIFICATION OF SUSPICIOUS PIGMENTED LESIONS (SPLS) IN PRIMARY CARE SETTINGS CAN LEAD TO IMPROVED MELANOMA PROGNOSIS AND A POSSIBLE 20- FOLD REDUCTION IN TREATMENT COST. THE PROPOSED DEVICE SIGNIFICANTLY REDUCES THE CLINICIANS' TIME REQUIRED FOR DOCUMENTING LESIONS AND FOR MAKING DIAGNOSTIC DECISIONS, THEREBY ALLOWING THE HEALTHCARE SYSTEM TO BETTER COPE WITH THE FORECASTED SHORTAGES OF DERMATOLOGISTS. THE PROPOSED TECHNOLOGY IS NOVEL IN THAT IT: 1) PROVIDES A STANDARDIZED WAY OF REFERRING TO LESIONS' LOCATIONS, 2) ALLOWS DERMATOLOGISTS TO MAINTAIN A COMPLETE HISTORICAL RECORD OF EVERY LESION 3) DETECT SIGNIFICANTLY CHANGED (EVOLVED) LESIONS AND 4) ASSISTS DERMATOLOGISTS IN FINDING CANCEROUS LESIONS AT THEIR VERY EARLY STAGES TO IMPROVE OVERALL PATIENT PROGNOSIS. THE PROJECT TEAM HAS ALREADY DEVELOPED A TOTAL BODY PHOTOGRAPHY (TBP) SYSTEM THAT IS UNLIKE THE COMMERCIALLY AVAILABLE SYSTEMS IN THAT IT OBVIATES THE NEED FOR USING A DERMATOSCOPE AND CAN PRODUCE IMAGES OF SUFFICIENT RESOLUTION THAT CAN BE USED FOR EARLY DETECTION OF SKIN CANCERS. THIS DEVICE HAS ALREADY RECEIVED AN IRB AND HAS BEEN INSTALLED AT JOHNS HOPKINS (JHU) OUTPATIENT CENTER FOR ITS FIRST CLINICAL STUDY. BY YOUR READING OF THIS PROPOSAL IS UNDER REVIEW, JHU'S 100-PATIENT STUDY IN WHICH THE EFFICACY OF SCAN-BASED EXAMINATIONS WILL BE COMPARED WITH THE EFFICACY OF TRADITIONAL CLINICAL AND DERMATOSCOPIC-BASED SKIN EXAMINATIONS, IS WELL ON ITS WAY. WITHIN THIS PROPOSAL TEAM INTENDS TO DEVELOP A TEMPORAL STUDY TOOL THAT CAN FOLLOW ALL PSLS OVER TIME REGARDLESS OF PARTICIPANTS' POSE AND WEIGHT CHANGES BETWEEN SCANNING SESSIONS. SUCH A SYSTEM WILL ENABLE CLINICIANS TO ACCURATELY MONITOR PATIENTS' PSLS OVER TIME, DOCUMENT ANY CHANGES IN PREVIOUSLY IDENTIFIED LESIONS, AND DETECT NEW LESIONS AT THE POINT OF CARE. WITHIN, THE TWO PHASES OF THIS PROJECT, THE TEAM WILL ALSO FOCUS ON DETECTING EVOLVED LESIONS AND OPTIMIZING THE SCANNING SOFTWARE TO PROVIDE A BETTER USER INTERFACE FOR FOLLOWING AND DIAGNOSING PIGMENTED SKIN LESIONS (PSL) WHILE REDUCING THE AMOUNT OF TIME IT TAKES FOR THE DERMATOLOGIST TO FULLY DOCUMENT THE PATIENTS LESIONS OF INTEREST. THOUGH SOME LITERATURE SUGGESTS THE EPIDEMY IN MELANOMA IS THE RESULT OF OVER-SCREENING AS EVIDENCED BY THE NUMBER OF DEATHS NOT INCREASING COMMENSURATELY, OTHERS SUGGEST THAT THE LOW DEATH-RATE IS THE RESULT OF BETTER SCREENING. REGARDLESS, THERE IS UNANIMOUS AGREEMENT THAT TOO MANY LESIONS ARE STUDIED BY PATHOLOGISTS. LUMO SCANNER WHEN COMBINED WITH THE FACILITIES DEVELOPED IN THIS PROJECT, WILL ENABLE TECHNICIANS PERFORM HIGHLY ACCURATE SCANS AND THUS ALLOW THE DERMATOLOGIST TO SPEND LESS DOCUMENTING THE HIGH-RISK PATIENTS. ALSO, THIS NOVEL DEVICE WILL ENABLE TELEDERMATOLOGY IN AREAS WHERE THERE IS A SCARCITY OF DERMATOLOGISTS. ADDITIONALLY, THE PROPOSED DEVICE CAN ALSO BE USED FOR DIAGNOSING AND ACCURATELY MONITORING THE EFFICACY OF THERAPIES FOR PSORIASIS, ATOPIC DERMATITIS, AND OTHER INFLAMMATORY SKIN CONDITIONS. PSORIASIS AND ATOPIC DERMATITIS ARE ALSO SERIOUS GLOBAL PROBLEMS. IN THE UNITED STATES, PSORIASIS AFFECTS ABOUT 8 MILLION PEOPLE WHILE ABOUT 31.6 MILLION PEOPLE IN THE UNITED STATES HAVE SOME FORM OF ECZEMA, INCLUDING ATOPIC DERMATITIS.